Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck KGaA | 163 |
| 2 | Baxter International Inc | 13 |
| 3 | BASF SE | 9 |
| 4 | Pfizer Inc | 9 |
| 5 | University of Toronto | 7 |
| 6 | Abbott Laboratories | 6 |
| 7 | Intellectual Ventures LLC | 6 |
| 8 | University of California | 6 |
| 9 | University of Minnesota System | 6 |
| 10 | Columbia University | 5 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 398 |
| 2 | A61P | Therapeutic activity (drug indications) | 233 |
| 3 | A61Q | Cosmetics, personal care | 194 |
| 4 | C07K | Peptides | 101 |
| 5 | C07D | Heterocyclic compounds | 79 |
| 6 | A01N | Preservation of bodies; biocides; pest repellents | 71 |
| 7 | C07C | Acyclic and carbocyclic compounds | 52 |
| 8 | C12N | Microorganisms, enzymes | 44 |
| 9 | A61M | Devices for introducing media into the body | 36 |
| 10 | A61L | Sterilising / disinfecting materials | 34 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| METHOD AND COMPOSITION FOR DETERMINING D-GLYCEROALDEHYDE-3-PHOSPHORIC ACID, INOGANIC PHOSPHORUS, OR 1,3-DIPHOSPHOGLYCERIC ACID IN HIGH SENSITIVITY | 1992 | Asahi Kasei Corp | 7 |
| A FORMULATION AND A PROCESS FOR REDUCING THE DETERIORATION OF RBCs OF BLOOD DURING STORAGE WITH PARTICULAR REFERENCE TO DECREASE IN THE LEVEL OF 2,3 DIPHOSPHOGLYCERATE | 2004 | 6 | |
| Cosmetic and dermatological formulations using cyclic 2,4-diphosphoglycerate (cDGP) and / or derivatives | 2004 | 4 | |
| Application of phthalide compound in preparing medicine for treating Alzheimer disease and abnormal metabolism of 2, 3-diphosphoglycerate | 2017 | 1 | |
| Use of cyclic 2,4-diphosphoglycerate (cDGP) and / or derivatives in cosmetic and dermatological formulations | 2002 | 1 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 13 |
| 2017 | 11 |
| 2018 | 4 |
| 2019 | 11 |
| 2020 | 5 |
| 2021 | 6 |
| 2022 | 9 |
| 2023 | 7 |
| 2024 | 8 |
| 2025 | 2 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Bruno Giardina | University of Rome Tor Vergata | 9 |
| 2 | Kouichi R. Tanaka | Harbor–UCLA Medical Center | 8 |
| 3 | Yang Xia | The University of Texas Health Science Center at Houston | 7 |
| 4 | Alvarez-Sala Jl | 7 | |
| 5 | Gary Moroff | American Red Cross | 6 |
| 6 | Rodney E. Kellems | The University of Texas Health Science Center at Houston | 6 |
| 7 | Fumihiko Sakakibara | Nagoya University | 6 |
| 8 | James M. Manning | Rockefeller University | 6 |
| 9 | Claes F. Högman | Uppsala University Hospital | 6 |
| 10 | Josep Carreras | Universitat de Barcelona | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Operation Everest II: oxygen transport during exercise at extreme simulated altitude | 1988 | 418 | Chronic Obstructive Pulmonary Disease (COPD) Research |
| Respiratory Function of Hemoglobin | 1998 | 301 | Neonatal Health and Biochemistry |
| A Randomized Study of Phosphate Therapy in the Treatment of Diabetic Ketoacidosis* | 1983 | 246 | Pancreatic function and diabetes |
| Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia | 2016 | 217 | Autophagy in Disease and Therapy |
| The Effect of Sepsis on the Erythrocyte | 2017 | 202 | Blood properties and coagulation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of 2,3-Diphosphoglyceric Acid?
Which organization holds the most patents related to 2,3-Diphosphoglyceric Acid?
What are the most common patent classifications for 2,3-Diphosphoglyceric Acid?
Which researcher has published the most papers on 2,3-Diphosphoglyceric Acid?
What are the common alternative names for 2,3-Diphosphoglyceric Acid?